YOLFTbeta
Celcuity LLC

Celcuity LLC

CELC · NASDAQ · Healthcare / Biotechnology

64.37USD+0.20 (+0.31%)

Price History

Full chart

Market Stats

Previous Close64.17
Open64.20
Day Range61.71 – 64.60
52-Week Range44.42 – 151.02
Volume641.53K
Market Cap3.88B
P/E (TTM)0.00
Forward P/E0.00
EPS-4.27
Dividend Yield0.00%
Beta0.20
50-Day Avg88.69
200-Day Avg105.20

About

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Brian F. Sullivan
  • Employees155
  • Headquarters2800 Campus Drive, Minneapolis, MN, United States, 55441, USA
  • Websitehttps://www.celcuity.com

Leadership

  • Mr. Brian F. SullivanCo-Founder, Chairman & CEO · b. 1962
  • Dr. Lance G. Laing Ph.D.Co-Founder, Chief Science Officer, VP, Secretary & Director · b. 1962
  • Ms. Vicky Hahne CPAChief Financial Officer · b. 1966
  • Ms. Jodi SieversHead of Investor Relations & Corporate Communications
  • Ms. Sheri SmithActing Head of Clinical Operations
  • Mr. Igor Gorbatchevsky M.D.Chief Medical Officer
  • Mr. Eldon C. Mayer III, M.B.A.Chief Commercial Officer · b. 1961

Financials

Income Statement

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue0000000000154.00K
Cost of Revenue58.38K73.06K104.70K223.04K339.00K385.59K303.24K210.92K142.77K129.95K167.00K
Gross Profit-58.38K-73.06K-104.70K-223.04K-339.00K-385.59K-303.24K-210.92K-142.77K-129.95K-167.00K
Gross Margin-----------108.44%
Operating Expense2.20M3.26M5.85M7.71M7.47M9.17M28.05M39.18M66.09M113.14M172.03M
Operating Income-2.26M-3.33M-5.95M-7.93M-7.81M-9.56M-28.36M-39.39M-66.23M-113.27M-172.19M
Operating Margin-----------111812.99%
EBITDA-2.20M-3.26M-5.85M-7.71M-7.47M-9.17M-28.04M-38.05M-58.31M-101.37M-159.73M
EBITDA Margin-----------103718.83%
Net Income-2.26M-3.31M-6.25M-7.48M-7.36M-9.47M-29.61M-40.37M-63.78M-111.78M-177.04M
Net Income Margin-----------114962.34%
R&D2.01M3.06M4.98M6.33M6.27M7.68M25.76M35.29M60.59M104.20M145.00M
R&D as % of Total Revenue----------94152.60%
Interest Expense00451.66K1111591201.26M2.11M5.33M10.28M17.15M
Interest Expense % of Total Revenue----------11135.06%

Balance Sheet

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets5.30M6.06M31.97M26.03M20.28M12.96M85.91M175.70M191.22M245.12M466.56M
Total Liabilities283.60K445.36K578.05K682.21K983.23K1.25M17.20M41.93M51.45M129.50M366.00M
Total Equity5.02M5.61M31.39M25.35M19.30M11.70M68.71M133.77M139.77M115.62M100.56M
Cash5.07M5.86M2.64M15.94M18.74M11.64M84.29M24.57M30.66M22.51M165.70M
Total Debt---25.61K256.14K262.49K14.89M35.24M37.45M97.95M195.38M
Net Debt-5.07M-5.86M-2.64M-15.92M-18.48M-11.38M-69.40M10.67M6.78M75.44M29.68M

Cash Flow

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.98M-2.89M-4.95M-6.08M-6.00M-7.15M-20.31M-36.01M-53.81M-83.47M-153.28M
Investing Cash Flow-78.98K-40.90K-28.98M19.09M8.53M-89.37K-81.40K-144.03M-5.01M-63.07M-64.08M
Financing Cash Flow4.80M3.72M30.71M236.70K259.31K137.97K93.04M120.33M64.91M138.39M360.55M
Capital Expenditure78.98K40.90K239.85K629.61K380.20K89.37K81.90K158.77K97.64K249.88K249.00K
Free Cash Flow-2.06M-2.93M-5.19M-6.71M-6.38M-7.24M-20.39M-36.17M-53.91M-83.72M-153.53M
Dividends Paid--0--------
FCF to OCF103.99%101.42%104.85%110.36%106.34%101.25%100.40%100.44%100.18%100.30%100.16%
Dividend Paid to FCF--0.00%--------

Earnings

Report DateSep 20, 2017Nov 13, 2017Mar 15, 2018May 14, 2018Aug 9, 2018Nov 13, 2018Feb 26, 2019May 7, 2019Aug 8, 2019Nov 7, 2019Mar 12, 2020May 7, 2020Aug 10, 2020Nov 9, 2020Feb 16, 2021May 10, 2021Aug 9, 2021Nov 8, 2021Mar 23, 2022May 16, 2022Aug 11, 2022Nov 10, 2022Mar 23, 2023May 15, 2023Aug 10, 2023Nov 13, 2023Mar 27, 2024May 15, 2024Aug 14, 2024Nov 14, 2024Mar 25, 2025May 14, 2025Aug 14, 2025Nov 12, 2025Mar 19, 2026May 14, 2026Aug 13, 2026Nov 11, 2026
EPS Estimate--0.19-0.15-0.19-0.17-0.18-0.18-0.20-0.18-0.17-0.18-0.17-0.18-0.23-0.22-0.20-0.21-0.24-0.35-0.51-0.48-0.60-0.44-0.43-0.46-0.53-0.75-0.71-0.55-0.70-0.67-0.86-0.84-0.96-1.05-0.89-1.08-1.45
EPS Actual-0.11-0.20-0.14-0.16-0.15-0.15-0.15-0.16-0.15-0.16-0.14-0.17-0.17-0.24-0.21-0.21-0.66-0.35-0.37-0.53-0.55-0.75-0.69-0.47-0.58-0.78-0.61-0.64-0.58-0.65-0.75-0.81-0.93-0.78-0.73-0.86-1.44-
Surprise--5.26%6.67%15.79%11.76%16.67%16.67%20.00%16.67%5.88%22.22%0.00%5.56%-4.35%4.55%-5.00%-214.29%-45.83%-5.71%-3.92%-14.58%-25.00%-56.82%-9.30%-26.09%-47.17%18.67%9.86%-5.45%7.14%-11.94%5.81%-10.71%18.75%30.48%3.37%-33.33%-
TimingAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap3.88B
Enterprise Value3.91B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book78.90
EPS-4.27
Book Value-0.261
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-208.48M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-1433.70%
Return on Assets-25.78%
Shares Outstanding48.93M
Shares Float29.72M
Beta0.20
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 7 analystsTarget 160.75
  • Strong Buy
    5
  • Buy
    2

Ownership Breakdown

Institutions
110.31%
Insiders
10.23%
Retail / Other
0.00%

Top Institutional Holders

  • Baker Bros Advisors LP
    7.92M16.18%
  • venBio Select Advisor LLC
    3.38M6.90%
  • Perceptive Advisors LLC
    3.20M6.53%
  • RTW INVESTMENTS, LLC
    3.04M6.21%
  • BlackRock Inc
    2.71M5.54%
  • NEA Management Company, LLC
    2.29M4.67%
  • Vanguard Capital Management, LLC
    1.78M3.64%
  • Deerfield Management Co
    1.71M3.50%
  • Soleus Capital Management, L.P.
    1.70M3.48%
  • State Street Corp
    1.52M3.10%
  • Morgan Stanley - Brokerage Accounts
    1.35M2.75%
  • T. Rowe Price Associates, Inc.
    1.28M2.62%
  • TANG CAPITAL MANAGEMENT LLC
    1.05M2.15%
  • Wellington Management Company LLP
    906.60K1.85%
  • Geode Capital Management, LLC
    891.07K1.82%
  • The Toronto-Dominion Bank
    882.76K1.80%
  • The Goldman Sachs Group Inc
    764.98K1.56%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    1.40M2.86%
  • State Street® SPDR® S&P® Biotech ETF
    1.19M2.43%
  • iShares Russell 2000 ETF
    979.70K2.00%